{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-120731","form_type":"8-K/A","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.165260+00:00","generated_at":"2026-06-07T22:09:08.318061+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunome files Morphimmune historical financials: 2022 net loss $7.5M, cash $7.2M","bullets":["Morphimmune 2022 net loss of $7.5M (2021: $2.8M); accumulated deficit $11.2M as of Dec 31, 2022.","As of Dec 31, 2022, cash $7.2M, total assets $7.3M, total liabilities $0.8M.","R&D expense $4.2M in 2022 (2021: $0.5M); G&A $3.3M (2021: $1.6M).","Merger closed Sep 29, 2023; pro forma combined financials filed as Exhibit 99.3."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-120731","json":"https://secwatch.observer/filing/0001104659-23-120731.json","markdown":"https://secwatch.observer/filing/0001104659-23-120731.md","text":"https://secwatch.observer/filing/0001104659-23-120731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923120731/0001104659-23-120731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923120731/tm2330767d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:09:08.318061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}